CVS CVS Health
FY2025 10-K
CVS Health (CVS) filed its fiscal year 2025 10-K annual report with the SEC on Feb 10, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business risk focus on compliance with extensive laws, regulations, and contractual requirements in healthcare sectors
- • Increased litigation exposure due to vertical integration strategy and expanded healthcare services
Management Discussion & Analysis
- • No revenue or profitability data disclosed in this MD&A section
- • Market valuation risk: $3.6B fair value decline in long-term debt with 100bp rate increase; no impact on operations
Risk Factors
- • Opioid litigation risk: $320 million accrual increase for ongoing opioid litigation matters in 2025
- • Geopolitical/macroeconomic exposure: Medicare Advantage segment served 37 million people, sensitive to CMS policy changes
Financial SummaryXBRL
Revenue
$402.1B
Net Income
$1.8B
Operating Margin
1.2%
Net Margin
0.4%
ROE
2.4%
Total Assets
$253.5B
EPS (Diluted)
$1.39
Operating Cash Flow
$10.6B
Source: XBRL data from CVS Health FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on CVS Health
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.